Altria’s Trading Volume Surges 78% on Strong EPS Outlook as Oral Tobacco Shift Defies Smokeable Slump

Generated by AI AgentAinvest Market Brief
Wednesday, Jul 30, 2025 10:25 pm ET1min read
Aime RobotAime Summary

- Altria's stock surged 3.61% with $1.25B trading volume, driven by narrowed 2025 EPS guidance to $5.35–$5.45.

- Oral tobacco revenue grew 5.9% as smokeable products declined 10.2% due to e-vapor shift and illicit competition.

- $4B shareholder returns and $274M buybacks supported Q2 adjusted EPS growth of 8.3% to $1.44.

- Strategic focus on smoke-free products and cost optimization aims to offset tariffs and regulatory risks.

On July 30, 2025,

(MO) saw a trading volume of $1.25 billion, a 78.47% surge from the prior day, and its stock price rose 3.61%, outperforming broader market trends. The company reported 2025 second-quarter and first-half results, narrowing its full-year adjusted diluted EPS guidance to $5.35–$5.45, reflecting a projected 3–5% growth from 2024’s $5.19. Adjusted EPS for Q2 increased 8.3% to $1.44, driven by higher operating income and reduced share counts via $274 million in repurchases. Shareholder returns totaled $4 billion in H1 2025 through dividends and buybacks.

The oral tobacco segment, led by on! nicotine pouches, became a key growth driver, offsetting declines in the smokeable products segment. Smokeable products faced a 10.2% drop in domestic cigarette shipments year-on-year, attributed to shifting consumer preferences toward e-vapor and illicit products. Altria’s oral tobacco revenue rose 5.9%, with adjusted operating income up 10.9%, underscoring the segment’s resilience. The company emphasized transitioning to smoke-free products and investing in research to align with long-term strategic goals.

Full-year guidance accounts for higher tariffs, regulatory challenges, and potential disruptions from illicit tobacco products. Despite these headwinds, Altria plans to reinvest cost savings from its Optimize & Accelerate initiative and maintain a 23–24% effective tax rate. Capital expenditures are projected between $175–225 million, with depreciation and amortization expenses around $290 million. The company remains cautious about macroeconomic uncertainties, including inflation and litigation risks, which could impact future performance.

A backtest of a strategy purchasing the top 500 high-volume stocks and holding for one day showed a 166.71% return from 2022 to 2025, outpacing the 29.18% benchmark. This approach achieved a 31.89% compound annual growth rate, highlighting the potential of liquidity-focused, short-term trading in capturing market momentum. However, such strategies require rigorous risk management due to their exposure to daily volatility and the need for precise execution.

Comments



Add a public comment...
No comments

No comments yet